State Street’s Creative Medical Technology CELZ Stock Holding History

State Street’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,547	Closed	-$12.7K	–	4685
2023 Q1	$12.7K	Hold	2,547	–	–	﹤0.01%	4729
2022 Q4	$9.29K	Hold	2,547	–	–	﹤0.01%	4810
2022 Q3	$11K	Hold	2,547	–	–	﹤0.01%	4886
2022 Q2	$19K	Buy	2,547 +250	+11%	+$4.03K	﹤0.01%	4877
2022 Q1	$90K	Buy	+2,297	New	+$51.1K	﹤0.01%	4671

Other funds holding CELZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

ODG

O'Dell Group Cincinnati, Ohio $466M AUM 13.5% 1-Year Est. Return

State Street's CELZ Position: Q2 2023 in Review

State Street sold out of Creative Medical Technology (CELZ) in Q2 2023, closing a stake of 2,547 shares — an estimated $12.7K sold.

State Street first reported a position in CELZ in Q1 2022 and held it in 5 quarters. The position peaked at $90K in Q1 2022. 9 funds tracked by Wall St. Rank hold CELZ as of Q2 2023.

State Street reported no remaining Creative Medical Technology position as of Q2 2023 after selling out during the quarter.
State Street sold 2,547 Creative Medical Technology shares in Q2 2023, an estimated $12.7K.
State Street first reported a position in Creative Medical Technology in Q1 2022 and held it in 5 quarters.
State Street's Creative Medical Technology position peaked at $90K in Q1 2022.
9 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.